RESUMEN
IL-27 exerts profound anti-inflammatory effects in several experimental autoimmune models, suggesting that it may be therapeutically relevant in SLE. To evaluate IL-27 level in SLE patients and its association to clinical manifestations, disease activity parameters and management strategy. We studied 80 SLE patients and 50 controls in a cross sectional study. Demographic, clinical and serological data were evaluated. Systemic lupus erythematosus disease activity index [SLEDAI] and Systemic Lupus International Collaboration Clinics/ACR damage index [SLICC] were assessed. Serum IL-27 was measured by ELISA. There was statistically significant difference in IL-27 level in SLE patients and healthy controls [9.7 +/- 21.9 pg/ml vs 20.2 +/- 47.3 pg/ml in SLE vs controls, respectively] [p = 0.04], also it was found that IL-27 level was statistically significantly lower in SLE patients with lupus nephritis [p = 0.02] and cerebritis [p = 0.03]. Interleukin 27 level had a statistically significant negative correlation with the cumulative dose of hydroxychloroquine and azathioprine [r = -0.3, p = 0.03 and r = -0.3 and p = 0.04, respectively]. IL-27 has anti-inflammatory effect in SLE patients especially those without nephritis or cerebritis and can be therapeutically relevant in SLE. To confirm our results we propose larger scale, multicentre studies with longer evaluation periods